Global Information
회사소개 | 문의 | 비교리스트

다발성 경화증 : 역학 및 환자 기반 시장 예측, 치료 알고리즘, 출시 및 개발중인 약제 분석

Multiple Sclerosis Forecast and Market Analysis to 2025

리서치사 Datamonitor Healthcare
발행일 2018년 07월 상품 코드 365215
페이지 정보 영문 765 Pages
가격
US $ 22,000 ₩ 25,988,000 PDF by E-mail (Single User License)
US $ 107,800 ₩ 127,344,000 PDF by E-mail (Global License)


다발성 경화증 : 역학 및 환자 기반 시장 예측, 치료 알고리즘, 출시 및 개발중인 약제 분석 Multiple Sclerosis Forecast and Market Analysis to 2025
발행일 : 2018년 07월 페이지 정보 : 영문 765 Pages

다발성 경화증 치료제 시장은 잠재적인 시장 규모가 큰 것으로 생각되지만, 그런 만큼 신규 진출 기업이나 (임상시험 최종 단계의) 파이프라인 후보의약품 등이 기존 기업/제품으로부터 시장 점유율을 확보하려 하고 있어 시장 경쟁은 매우 치열해질 전망입니다.

다발성 경화증(Multiple Sclerosis)의 출시 및 임상시험중인(파이프라인상) 치료제에 대해 조사했으며, 각 제품의 시장 규모 추정, 신약 출시에 의한 시장 규모 변동 전망, 현재·향후 대표적 제품, 질환 종류(아류형)별 상황, 의사가 직면하고 있는 여러 문제 등의 정보를 전해드립니다.

1. 예측 : 다발성 경화증

  • 주요 요약
  • 시장 개요와 동향
  • 시장 정의와 분석 방법
  • Aubagio(teriflunomide)
  • Avonex(interferon beta-1a)
  • Betaseron/Betaferon(interferon beta-1b)
  • Copaxone(glatiramer acetate)
  • Extavia(interferon beta-1b)
  • Gilenya(fingolimod)
  • Lemtrada(alemtuzumab)
  • Nerventra(laquinimod)
  • ocrelizumab
  • ozanimod
  • Plegridy(peginterferon beta-1a)
  • ponesimod
  • Rebif(interferon beta-1a)
  • siponimod
  • Tecfidera(dimethyl fumarate)
  • Tysabri(natalizumab)
  • Zinbryta(daclizumab)
  • 1차 조사 방법

2. 치료 : 다발성 경화증

  • 주요 요약
  • 1차 조사 방법
  • 질환의 정의와 진단 방법
  • 환자 세분화
  • 국가별 치료 트리
  • 현재 치료 옵션
  • 처방 동향
  • 다발성 경화증 관련 미충족 요구

3. 역학 : 다발성 경화증

  • 주요 요약
  • 질환 배경
  • 세계 전체 동향과의 차이
  • 위험인자
  • 정보 출처와 조사 방법
  • 시장 예측
  • 역학자의 분석
  • 강점과 제약

4. 출시된 약제 : 다발성 경화증

  • 주요 요약
  • 제품 개요
  • 부록
  • 제품 프로파일 : Ampyra
  • 제품 프로파일 : Aubagio
  • 제품 프로파일 : Avonex
  • 제품 프로파일 : Betaseron
  • 제품 프로파일 : Copaxone
  • 제품 프로파일 : Extavia
  • 제품 프로파일 : Gilenya
  • 제품 프로파일 : Lemtrada
  • 제품 프로파일 : Plegridy
  • 제품 프로파일 : Rebif
  • 제품 프로파일 : Tecfidera
  • 제품 프로파일 : Tysabri

5. 파이프라인 제품 : 다발성 경화증

  • 주요 요약
  • 임상시험 파이프라인 개요
  • 부록
  • 제품 프로파일(최종 단계) : Nerventra
  • 제품 프로파일(최종 단계) : Zinbryta
  • 제품 프로파일(최종 단계) : ocrelizumab
  • 제품 프로파일(최종 단계) : ozanimod
  • 제품 프로파일(최종 단계) : ponesimod
  • 제품 프로파일(최종 단계) : siponimod
KSM 16.08.22

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

OVERVIEW:

Multiple sclerosis (MS) is an inflammatory, autoimmune disease characterized by neuronal demyelination leading to physical and cognitive disability. Although the etiology of MS is uncertain, it is thought to involve genetic, environmental, and infectious disease components. Current therapies for MS largely fall into two categories: symptomatic and disease-modifying, and both are frequently used in combination with one another.

MARKET SNAPSHOT:

  • Ocrevus's peak sales estimate increases as early data suggest it is competing across a range of treatment settings.
  • Despite the approvals of newer, more efficacious therapies, Copaxone and interferon beta remain key components of treatment practices in MS.
  • Despite negative population growth in some markets, an overall increase in diagnosed prevalent cases of MS is expected.
  • Exciting newcomer Ocrevus is gaining considerable traction in only its first year of commercial availability.
  • Celgene must balance ozanimod pricing to maximize MS opportunity while ensuring reimbursement in secondary indications.
  • Products targeting progressive disease types will have favorable reimbursement.

TABLE OF CONTENTS

FORECAST: MULTIPLE SCLEROSIS (Published on 24 November 2017)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • RECENT FORECAST UPDATES
  • MARKET DYNAMICS
  • FORECAST AND FUTURE TRENDS
  • MARKET DEFINITION AND METHODOLOGY
  • PRIMARY RESEARCH METHODOLOGY
  • BIBLIOGRAPHY
  • PRODUCT PROFILE (LATE STAGE): ALKS 8700
  • PRODUCT PROFILE: AUBAGIO
  • PRODUCT PROFILE: AVONEX
  • PRODUCT PROFILE: BETASERON
  • PRODUCT PROFILE: COPAXONE
  • PRODUCT PROFILE: GILENYA
  • PRODUCT PROFILE: LEMTRADA
  • PRODUCT PROFILE: MAVENCLAD
  • PRODUCT PROFILE: OCREVUS
  • PRODUCT PROFILE: PLEGRIDY
  • PRODUCT PROFILE: REBIF
  • PRODUCT PROFILE: TECFIDERA
  • PRODUCT PROFILE: TYSABRI
  • PRODUCT PROFILE: ZINBRYTA
  • PRODUCT PROFILE (LATE STAGE): OFATUMUMAB
  • PRODUCT PROFILE (LATE STAGE): OZANIMOD
  • PRODUCT PROFILE (LATE STAGE): PONESIMOD
  • PRODUCT PROFILE (LATE STAGE): SIPONIMOD
  • PRODUCT PROFILE (LATE STAGE): UBLITUXIMAB

TREATMENT: MULTIPLE SCLEROSIS (Published on 17 November 2017)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • PRIMARY RESEARCH METHODOLOGY
  • DISEASE DEFINITION AND DIAGNOSIS
  • PATIENT SEGMENTATION
  • CURRENT TREATMENT OPTIONS
  • PRESCRIBING TRENDS
  • UNMET NEEDS IN MULTIPLE SCLEROSIS

EPIDEMIOLOGY: MULTIPLE SCLEROSIS (Published on 18 July 2018)

  • OVERVIEW
  • DISEASE BACKGROUND
  • METHODOLOGY
  • FORECAST
  • BIBLIOGRAPHY
  • APPENDIX: ADDITIONAL SOURCES

MARKETED DRUGS: MULTIPLE SCLEROSIS (Published on 24 November 2017)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • PRODUCT OVERVIEW
  • PRODUCT PROFILE: AUBAGIO
  • PRODUCT PROFILE: AVONEX
  • PRODUCT PROFILE: BETASERON
  • PRODUCT PROFILE: COPAXONE
  • PRODUCT PROFILE: GILENYA
  • PRODUCT PROFILE: LEMTRADA
  • PRODUCT PROFILE: MAVENCLAD
  • PRODUCT PROFILE: OCREVUS
  • PRODUCT PROFILE: PLEGRIDY
  • PRODUCT PROFILE: REBIF
  • PRODUCT PROFILE: TECFIDERA
  • PRODUCT PROFILE: TYSABRI
  • PRODUCT PROFILE: ZINBRYTA

MULTIPLE SCLEROSIS PRICING, REIMBURSEMENT, AND ACCESS (Published on 25 July 2017)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • REGULATORY LABELS
  • GLOBAL ACCESS LEVERS
  • EVIDENCE AND VALUE
  • ACCESS TO RECENTLY APPROVED AND PIPELINE PRODUCTS
  • PRICING
  • US
  • JAPAN
  • FRANCE
  • GERMANY
  • ITALY
  • SPAIN
  • UK
  • METHODOLOGY

PIPELINE: MULTIPLE SCLEROSIS (Published on 24 November 2017)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • CLINICAL PIPELINE OVERVIEW
  • ADDITIONAL PHARMA INTELLIGENCE PIPELINE RESOURCES
  • PRODUCT PROFILE (LATE STAGE): ALKS 8700
  • PRODUCT PROFILE (LATE STAGE): OFATUMUMAB
  • PRODUCT PROFILE (LATE STAGE): OZANIMOD
  • PRODUCT PROFILE (LATE STAGE): PONESIMOD
  • PRODUCT PROFILE (LATE STAGE): SIPONIMOD
  • PRODUCT PROFILE (LATE STAGE): UBLITUXIMAB

LIST OF FIGURES

  • Figure 1: Multiple sclerosis - current and future market dynamics analysis
  • Figure 2: Datamonitor Healthcare's assessment summary of key marketed and pipeline drugs for multiple sclerosis
  • Figure 3: Multiple sclerosis market sales across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 4: Growth dynamics of the multiple sclerosis market across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 5: Multiple sclerosis market sales across the US, Japan, and five major EU markets, by disease subtype, 2016-25
  • Figure 6: Methodology flow for Datamonitor Healthcare's multiple sclerosis forecast
  • Figure 7: Price sources and calculations, by country
  • Figure 8: ALKS 8700 for multiple sclerosis - SWOT analysis
  • Figure 9: Datamonitor Healthcare's drug assessment summary of ALKS 8700 for multiple sclerosis
  • Figure 10: Datamonitor Healthcare's drug assessment summary of ALKS 8700 for multiple sclerosis
  • Figure 11: ALKS 8700 sales for multiple sclerosis across the US and five major EU markets, by country, 2016-25
  • Figure 12: Aubagio for multiple sclerosis - SWOT analysis
  • Figure 13: Datamonitor Healthcare's drug assessment summary for Aubagio in multiple sclerosis
  • Figure 14: Datamonitor Healthcare's drug assessment summary for Aubagio in multiple sclerosis
  • Figure 15: Aubagio sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 16: Avonex for multiple sclerosis - SWOT analysis
  • Figure 17: Datamonitor Healthcare's drug assessment summary for Avonex in multiple sclerosis
  • Figure 18: Datamonitor Healthcare's drug assessment summary for Avonex in multiple sclerosis
  • Figure 19: Avonex sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 20: Betaseron for multiple sclerosis - SWOT analysis
  • Figure 21: Datamonitor Healthcare's drug assessment summary for Betaseron in multiple sclerosis
  • Figure 22: Datamonitor Healthcare's drug assessment summary for Betaseron in multiple sclerosis
  • Figure 23: Betaseron sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 24: Copaxone for multiple sclerosis - SWOT analysis
  • Figure 25: Datamonitor Healthcare's drug assessment summary for Copaxone in multiple sclerosis
  • Figure 26: Datamonitor Healthcare's drug assessment summary for Copaxone in multiple sclerosis
  • Figure 27: Copaxone sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 28: Gilenya for multiple sclerosis - SWOT analysis
  • Figure 29: Datamonitor Healthcare's drug assessment summary for Gilenya in multiple sclerosis
  • Figure 30: Datamonitor Healthcare's drug assessment summary for Gilenya in multiple sclerosis
  • Figure 31: Gilenya sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 32: Lemtrada for multiple sclerosis - SWOT analysis
  • Figure 33: Datamonitor Healthcare's drug assessment summary for Lemtrada in multiple sclerosis
  • Figure 34: Datamonitor Healthcare's drug assessment summary for Lemtrada in multiple sclerosis
  • Figure 35: Lemtrada sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 36: Mavenclad for multiple sclerosis - SWOT analysis
  • Figure 37: Datamonitor Healthcare's drug assessment summary for Mavenclad in multiple sclerosis
  • Figure 38: Datamonitor Healthcare's drug assessment summary for cladribine in multiple sclerosis
  • Figure 39: Mavenclad sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 40: Ocrevus for multiple sclerosis - SWOT analysis
  • Figure 41: Datamonitor Healthcare's drug assessment summary for Ocrevus in multiple sclerosis
  • Figure 42: Datamonitor Healthcare's drug assessment summary for Ocrevus in multiple sclerosis
  • Figure 43: Ocrevus sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 44: Plegridy for multiple sclerosis - SWOT analysis
  • Figure 45: Datamonitor Healthcare's drug assessment summary for Plegridy in multiple sclerosis
  • Figure 46: Datamonitor Healthcare's drug assessment summary for Plegridy in multiple sclerosis
  • Figure 47: Plegridy sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 48: Rebif for multiple sclerosis - SWOT analysis
  • Figure 49: Datamonitor Healthcare's drug assessment summary for Rebif in multiple sclerosis
  • Figure 50: Datamonitor Healthcare's drug assessment summary for Rebif in multiple sclerosis
  • Figure 51: Rebif sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 52: Tecfidera for multiple sclerosis - SWOT analysis
  • Figure 53: Datamonitor Healthcare's drug assessment summary for Tecfidera in multiple sclerosis
  • Figure 54: Datamonitor Healthcare's drug assessment summary for Tecfidera in multiple sclerosis
  • Figure 55: Tecfidera sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 56: Tysabri for multiple sclerosis - SWOT analysis
  • Figure 57: Datamonitor Healthcare's drug assessment summary for Tysabri in multiple sclerosis
  • Figure 58: Datamonitor Healthcare's drug assessment summary for Tysabri in multiple sclerosis
  • Figure 59: Tysabri sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 60: Zinbryta for multiple sclerosis - SWOT analysis
  • Figure 61: Datamonitor Healthcare's drug assessment summary for Zinbryta in multiple sclerosis
  • Figure 62: Datamonitor Healthcare's drug assessment summary for Zinbryta in multiple sclerosis
  • Figure 63: Zinbryta sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 64: Ofatumumab for multiple sclerosis - SWOT analysis
  • Figure 65: Datamonitor Healthcare's drug assessment summary of ofatumumab for multiple sclerosis
  • Figure 66: Datamonitor Healthcare's drug assessment summary of ofatumumab for multiple sclerosis
  • Figure 67: Ozanimod for multiple sclerosis - SWOT analysis
  • Figure 68: Datamonitor Healthcare's drug assessment summary of ozanimod for multiple sclerosis
  • Figure 69: Datamonitor Healthcare's drug assessment summary of ozanimod for multiple sclerosis
  • Figure 70: Ozanimod sales for multiple sclerosis across the US and five major EU markets, by country, 2016-25
  • Figure 71: Ponesimod for multiple sclerosis - SWOT analysis
  • Figure 72: Datamonitor Healthcare's drug assessment summary of ponesimod for multiple sclerosis
  • Figure 73: Datamonitor Healthcare's drug assessment summary of ponesimod for multiple sclerosis
  • Figure 74: Ponesimod sales for multiple sclerosis across the US and five major EU markets, by country, 2016-25
  • Figure 75: Siponimod for multiple sclerosis - SWOT analysis
  • Figure 76: Datamonitor Healthcare's drug assessment summary of siponimod for multiple sclerosis
  • Figure 77: Datamonitor Healthcare's drug assessment summary of siponimod for multiple sclerosis
  • Figure 78: Siponimod sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 79: Ublituximab for multiple sclerosis - SWOT analysis
  • Figure 80: Datamonitor Healthcare's drug assessment summary of ublituximab for multiple sclerosis
  • Figure 81: Datamonitor Healthcare's drug assessment summary of ublituximab for multiple sclerosis
  • Figure 82: Disability accumulation in the three main clinical subtypes of multiple sclerosis
  • Figure 83: Segmentation of respondents' multiple sclerosis patients in the US, Japan, and five major EU markets, by disease subtype, 2016
  • Figure 84: RRMS patients who fall into each treatment category in the US, Japan, and five major EU markets, by country, 2016
  • Figure 85: PPMS patients who fall into each treatment category in the US, Japan, and five major EU markets, by country, 2016
  • Figure 86: SPMS patients who fall into each treatment category in the US, Japan, and five major EU markets, by country, 2016
  • Figure 87: Use of monotherapy or combination regimens of disease-modifying drugs, by disease subtype and line of therapy, 2016
  • Figure 88: Top five disease-modifying therapies used at first line in RRMS patients in the US, Japan, and five major EU markets, by country
  • Figure 89: Top five disease-modifying therapies used at second line and later in RRMS patients in the US, Japan, and five major EU markets, by country
  • Figure 90: Top five disease-modifying therapies used at first line in PPMS patients in the US, Japan, and five major EU markets, by country
  • Figure 91: Top five disease-modifying therapies used at second line and later in PPMS patients in the US, Japan, and five major EU markets, by country
  • Figure 92: Top five disease-modifying therapies used at first line in SPMS patients in the US, Japan, and five major EU markets, by country
  • Figure 93: Top five disease-modifying therapies used at second line and later in SPMS patients in the US, Japan, and five major EU markets, by country
  • Figure 94: Average compliance rates with disease-modifying therapies, by disease subtype and drug administration route, 2016
  • Figure 95: Key unmet needs in multiple sclerosis across the US, Japan, and five major EU markets, 2016
  • Figure 96: Trends in diagnosed prevalent cases of MS in the US, Japan, and five major EU markets, 2017-37
  • Figure 97: Aubagio for multiple sclerosis - SWOT analysis
  • Figure 98: Datamonitor Healthcare's drug assessment summary for Aubagio in multiple sclerosis
  • Figure 99: Datamonitor Healthcare's drug assessment summary for Aubagio in multiple sclerosis
  • Figure 100: Aubagio sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 101: Avonex for multiple sclerosis - SWOT analysis
  • Figure 102: Datamonitor Healthcare's drug assessment summary for Avonex in multiple sclerosis
  • Figure 103: Datamonitor Healthcare's drug assessment summary for Avonex in multiple sclerosis
  • Figure 104: Avonex sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 105: Betaseron for multiple sclerosis - SWOT analysis
  • Figure 106: Datamonitor Healthcare's drug assessment summary for Betaseron in multiple sclerosis
  • Figure 107: Datamonitor Healthcare's drug assessment summary for Betaseron in multiple sclerosis
  • Figure 108: Betaseron sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 109: Copaxone for multiple sclerosis - SWOT analysis
  • Figure 110: Datamonitor Healthcare's drug assessment summary for Copaxone in multiple sclerosis
  • Figure 111: Datamonitor Healthcare's drug assessment summary for Copaxone in multiple sclerosis
  • Figure 112: Copaxone sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 113: Gilenya for multiple sclerosis - SWOT analysis
  • Figure 114: Datamonitor Healthcare's drug assessment summary for Gilenya in multiple sclerosis
  • Figure 115: Datamonitor Healthcare's drug assessment summary for Gilenya in multiple sclerosis
  • Figure 116: Gilenya sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 117: Lemtrada for multiple sclerosis - SWOT analysis
  • Figure 118: Datamonitor Healthcare's drug assessment summary for Lemtrada in multiple sclerosis
  • Figure 119: Datamonitor Healthcare's drug assessment summary for Lemtrada in multiple sclerosis
  • Figure 120: Lemtrada sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 121: Mavenclad for multiple sclerosis - SWOT analysis
  • Figure 122: Datamonitor Healthcare's drug assessment summary for Mavenclad in multiple sclerosis
  • Figure 123: Datamonitor Healthcare's drug assessment summary for cladribine in multiple sclerosis
  • Figure 124: Mavenclad sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 125: Ocrevus for multiple sclerosis - SWOT analysis
  • Figure 126: Datamonitor Healthcare's drug assessment summary for Ocrevus in multiple sclerosis
  • Figure 127: Datamonitor Healthcare's drug assessment summary for Ocrevus in multiple sclerosis
  • Figure 128: Ocrevus sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 129: Plegridy for multiple sclerosis - SWOT analysis
  • Figure 130: Datamonitor Healthcare's drug assessment summary for Plegridy in multiple sclerosis
  • Figure 131: Datamonitor Healthcare's drug assessment summary for Plegridy in multiple sclerosis
  • Figure 132: Plegridy sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 133: Rebif for multiple sclerosis - SWOT analysis
  • Figure 134: Datamonitor Healthcare's drug assessment summary for Rebif in multiple sclerosis
  • Figure 135: Datamonitor Healthcare's drug assessment summary for Rebif in multiple sclerosis
  • Figure 136: Rebif sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 137: Tecfidera for multiple sclerosis - SWOT analysis
  • Figure 138: Datamonitor Healthcare's drug assessment summary for Tecfidera in multiple sclerosis
  • Figure 139: Datamonitor Healthcare's drug assessment summary for Tecfidera in multiple sclerosis
  • Figure 140: Tecfidera sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 141: Tysabri for multiple sclerosis - SWOT analysis
  • Figure 142: Datamonitor Healthcare's drug assessment summary for Tysabri in multiple sclerosis
  • Figure 143: Datamonitor Healthcare's drug assessment summary for Tysabri in multiple sclerosis
  • Figure 144: Tysabri sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 145: Zinbryta for multiple sclerosis - SWOT analysis
  • Figure 146: Datamonitor Healthcare's drug assessment summary for Zinbryta in multiple sclerosis
  • Figure 147: Datamonitor Healthcare's drug assessment summary for Zinbryta in multiple sclerosis
  • Figure 148: Zinbryta sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 149: ALKS 8700 for multiple sclerosis - SWOT analysis
  • Figure 150: Datamonitor Healthcare's drug assessment summary of ALKS 8700 for multiple sclerosis
  • Figure 151: Datamonitor Healthcare's drug assessment summary of ALKS 8700 for multiple sclerosis
  • Figure 152: ALKS 8700 sales for multiple sclerosis across the US and five major EU markets, by country, 2016-25
  • Figure 153: Ofatumumab for multiple sclerosis - SWOT analysis
  • Figure 154: Datamonitor Healthcare's drug assessment summary of ofatumumab for multiple sclerosis
  • Figure 155: Datamonitor Healthcare's drug assessment summary of ofatumumab for multiple sclerosis
  • Figure 156: Ozanimod for multiple sclerosis - SWOT analysis
  • Figure 157: Datamonitor Healthcare's drug assessment summary of ozanimod for multiple sclerosis
  • Figure 158: Datamonitor Healthcare's drug assessment summary of ozanimod for multiple sclerosis
  • Figure 159: Ozanimod sales for multiple sclerosis across the US and five major EU markets, by country, 2016-25
  • Figure 160: Ponesimod for multiple sclerosis - SWOT analysis
  • Figure 161: Datamonitor Healthcare's drug assessment summary of ponesimod for multiple sclerosis
  • Figure 162: Datamonitor Healthcare's drug assessment summary of ponesimod for multiple sclerosis
  • Figure 163: Ponesimod sales for multiple sclerosis across the US and five major EU markets, by country, 2016-25
  • Figure 164: Siponimod for multiple sclerosis - SWOT analysis
  • Figure 165: Datamonitor Healthcare's drug assessment summary of siponimod for multiple sclerosis
  • Figure 166: Datamonitor Healthcare's drug assessment summary of siponimod for multiple sclerosis
  • Figure 167: Siponimod sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 168: Ublituximab for multiple sclerosis - SWOT analysis
  • Figure 169: Datamonitor Healthcare's drug assessment summary of ublituximab for multiple sclerosis
  • Figure 170: Datamonitor Healthcare's drug assessment summary of ublituximab for multiple sclerosis

LIST OF TABLES

  • Table 1: Multiple sclerosis market sales across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 2: Multiple sclerosis market sales across the US, Japan, and five major EU markets, by formulation ($m), 2016-25
  • Table 3: Multiple sclerosis market sales across the US, Japan, and five major EU markets, by disease subtype ($m), 2016-25
  • Table 4: Multiple sclerosis market treated patient numbers across the US, Japan, and five major EU markets, by disease subtype, 2016-25
  • Table 5: Sales of the top three highest selling drugs in multiple sclerosis in 2025 across the US, Japan, and five major EU markets ($m), 2016-25
  • Table 6: Summary of drug classes and molecules included in Datamonitor Healthcare's multiple sclerosis patient-based forecast
  • Table 7: Exchange rates used for calculating prices
  • Table 8: Neurologists surveyed for the multiple sclerosis primary research study, 2016
  • Table 9: ALKS 8700 drug profile
  • Table 10: ALKS 8700 Phase III trials in multiple sclerosis
  • Table 11: ALKS 8700 sales for multiple sclerosis across the US and five major EU markets, by country ($m), 2016-25
  • Table 12: Aubagio drug profile
  • Table 13: Aubagio pivotal trial data in multiple sclerosis
  • Table 14: Aubagio sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 15: Avonex drug profile
  • Table 16: Avonex pivotal trial data in multiple sclerosis
  • Table 17: Avonex sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 18: Betaseron drug profile
  • Table 19: Betaseron pivotal trial data in multiple sclerosis
  • Table 20: Betaseron sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 21: Copaxone drug profile
  • Table 22: Copaxone pivotal trial data in multiple sclerosis
  • Table 23: Copaxone sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 24: Gilenya drug profile
  • Table 25: Gilenya pivotal trial data in multiple sclerosis
  • Table 26: Gilenya sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 27: Lemtrada drug profile
  • Table 28: Lemtrada pivotal trial data in multiple sclerosis
  • Table 29: Lemtrada sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 30: Mavenclad drug profile
  • Table 31: Mavenclad pivotal trial data in multiple sclerosis
  • Table 32: Mavenclad sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 33: Ocrevus drug profile
  • Table 34: Ocrevus pivotal trial data in multiple sclerosis
  • Table 35: Ocrevus sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 36: Plegridy drug profile
  • Table 37: Plegridy pivotal trial data in multiple sclerosis
  • Table 38: Plegridy sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 39: Rebif drug profile
  • Table 40: Rebif pivotal trial data in multiple sclerosis
  • Table 41: Rebif sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 42: Tecfidera drug profile
  • Table 43: Tecfidera pivotal trial data in multiple sclerosis
  • Table 44: Tecfidera sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 45: Tysabri drug profile
  • Table 46: Tysabri pivotal trial data in multiple sclerosis
  • Table 47: Tysabri sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 48: Zinbryta drug profile
  • Table 49: Zinbryta pivotal trial data in multiple sclerosis
  • Table 50: Zinbryta sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 51: Ofatumumab drug profile
  • Table 52: Ofatumumab Phase III trials in multiple sclerosis
  • Table 53: Ozanimod drug profile
  • Table 54: Ozanimod Phase III data in multiple sclerosis
  • Table 55: Ozanimod sales for multiple sclerosis across the US and five major EU markets, by country ($m), 2016-25
  • Table 56: Ponesimod drug profile
  • Table 57: Ponesimod Phase III trials in multiple sclerosis
  • Table 58: Ponesimod sales for multiple sclerosis across the US and five major EU markets, by country ($m), 2016-25
  • Table 59: Siponimod drug profile
  • Table 60: Siponimod Phase III data in multiple sclerosis
  • Table 61: Siponimod sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 62: Ublituximab drug profile
  • Table 63: Ublituximab Phase III trials in multiple sclerosis
  • Table 64: Neurologists surveyed for the multiple sclerosis primary research study, 2016
  • Table 65: Clinical subtypes of multiple sclerosis
  • Table 66: Multiple sclerosis diagnostic criteria
  • Table 67: Primary multiple sclerosis symptoms
  • Table 68: Leading disease-modifying therapies for multiple sclerosis
  • Table 69: Commonly used guidelines/consensus papers for the treatment of multiple sclerosis
  • Table 70: Multiple sclerosis patients treated with disease-modifying therapy in the US, Japan, and five major EU markets, by country (%), 2016
  • Table 71: Prescription trends in first-line RRMS patients in the US, Japan, and five major EU markets, by country (%), 2016
  • Table 72: Prescription trends in second-line and later RRMS patients in the US, Japan, and five major EU markets, by country (%), 2016
  • Table 73: Prescription trends in first-line PPMS patients in the US, Japan, and five major EU markets, by country (%), 2016
  • Table 74: Prescription trends in second-line and later PPMS patients in the US, Japan, and five major EU markets, by country (%), 2016
  • Table 75: Prescription trends in first-line SPMS patients in the US, Japan, and five major EU markets, by country (%), 2016
  • Table 76: Prescription trends in second-line and later SPMS patients in the US, Japan, and five major EU markets, by country (%), 2016
  • Table 77: Mean compliance rates with oral disease-modifying therapies in the US, Japan, and five major EU markets, by disease subtype and country, 2016
  • Table 78: Mean compliance rates with subcutaneous, injectable disease-modifying therapies, by disease subtype and country, 2016
  • Table 79: Side effects demonstrated by current multiple sclerosis treatments
  • Table 80: Sources used for the epidemiological analysis of MS in the US, Japan, and five major EU markets, by country
  • Table 81: Diagnosed prevalent cases of MS in the US, Japan, and five major EU markets, by country, 2017-37
  • Table 82: Profiled key marketed drugs for multiple sclerosis
  • Table 83: Aubagio drug profile
  • Table 84: Aubagio pivotal trial data in multiple sclerosis
  • Table 85: Aubagio sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 86: Avonex drug profile
  • Table 87: Avonex pivotal trial data in multiple sclerosis
  • Table 88: Avonex sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 89: Betaseron drug profile
  • Table 90: Betaseron pivotal trial data in multiple sclerosis
  • Table 91: Betaseron sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 92: Copaxone drug profile
  • Table 93: Copaxone pivotal trial data in multiple sclerosis
  • Table 94: Copaxone sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 95: Gilenya drug profile
  • Table 96: Gilenya pivotal trial data in multiple sclerosis
  • Table 97: Gilenya sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 98: Lemtrada drug profile
  • Table 99: Lemtrada pivotal trial data in multiple sclerosis
  • Table 100: Lemtrada sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 101: Mavenclad drug profile
  • Table 102: Mavenclad pivotal trial data in multiple sclerosis
  • Table 103: Mavenclad sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 104: Ocrevus drug profile
  • Table 105: Ocrevus pivotal trial data in multiple sclerosis
  • Table 106: Ocrevus sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 107: Plegridy drug profile
  • Table 108: Plegridy pivotal trial data in multiple sclerosis
  • Table 109: Plegridy sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 110: Rebif drug profile
  • Table 111: Rebif pivotal trial data in multiple sclerosis
  • Table 112: Rebif sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 113: Tecfidera drug profile
  • Table 114: Tecfidera pivotal trial data in multiple sclerosis
  • Table 115: Tecfidera sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 116: Tysabri drug profile
  • Table 117: Tysabri pivotal trial data in multiple sclerosis
  • Table 118: Tysabri sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 119: Zinbryta drug profile
  • Table 120: Zinbryta pivotal trial data in multiple sclerosis
  • Table 121: Zinbryta sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 122: Marketed products and approved indications for multiple sclerosis in the US, Japan, and five major EU markets
  • Table 123: Levers impacting access to multiple sclerosis drugs in the US and five major EU markets
  • Table 124: Pricing of key multiple sclerosis drugs in the US, Japan, and five major EU markets, by country
  • Table 125: Top multiple sclerosis drug prescriptions filled by Medicare beneficiaries participating in Part B and D programs, 2015
  • Table 126: Multiple sclerosis spend by payers, 2016
  • Table 127: Specialty drug spend by Express Scripts members, by payer type (multiple sclerosis market), 2016
  • Table 128: CVS Caremark's and Express Scripts' formulary exclusions for multiple sclerosis drugs
  • Table 129: Formulary placement of multiple sclerosis medications in selected commercial formularies
  • Table 130: Formulary placement of multiple sclerosis medications in selected Medicare formularies
  • Table 131: Formulary placement of multiple sclerosis medications, by region
  • Table 132: Prior authorization criteria for multiple sclerosis drugs in major health insurers and PBMs
  • Table 133: Multiple sclerosis drug pricing compared to ICER value-price benchmarks
  • Table 134: Japan - pricing premiums given to medicines that can demonstrate benefit over comparators
  • Table 135: Price calculation methodologies for multiple sclerosis drugs in Japan launched after 2008
  • Table 136: Transparency Committee's ASMR ratings and pricing implications
  • Table 137: Transparency Committee's SMR ratings and pricing implications
  • Table 138: Transparency Commission's assessment of multiple sclerosis treatments
  • Table 139: G-BA assessment of key multiple sclerosis therapies
  • Table 140: EMA labels and G-BA assessments for Gilenya
  • Table 141: Reimbursement conditions for multiple sclerosis treatments in Italy
  • Table 142: Italian regional formulary decisions for multiple sclerosis drugs
  • Table 143: Therapeutic positioning reports for multiple sclerosis drugs in Spain
  • Table 144: Spanish Society of Hospital Pharmacy ratings
  • Table 145: Regional MADRE assessments for multiple sclerosis drugs
  • Table 146: NICE assessments of key multiple sclerosis therapies
  • Table 147: UK regional formulary decisions for multiple sclerosis drugs, 2017
  • Table 148: SMC decisions on key multiple sclerosis therapies
  • Table 149: Price sources and calculations for the US
  • Table 150: Price sources and calculations for the EU
  • Table 151: Exchange rates used for calculating branded drug prices
  • Table 152: Profiled pipeline products in development for multiple sclerosis
  • Table 153: ALKS 8700 drug profile
  • Table 154: ALKS 8700 Phase III trials in multiple sclerosis
  • Table 155: ALKS 8700 sales for multiple sclerosis across the US and five major EU markets, by country ($m), 2016-25
  • Table 156: Ofatumumab drug profile
  • Table 157: Ofatumumab Phase III t
Back to Top
전화 문의
F A Q